<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04670172</url>
  </required_header>
  <id_info>
    <org_study_id>GHOR001</org_study_id>
    <nct_id>NCT04670172</nct_id>
  </id_info>
  <brief_title>Real-Life Chronic Rhinosinusitis Outcome Registry</brief_title>
  <official_title>Real-Life Chronic Rhinosinusitis Outcome Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Change Accelerator in Respiratory Care</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Change Accelerator in Respiratory Care</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An international consortium of leading medical experts in the field of chronic respiratory&#xD;
      disease, the research team of Galenus Health and the non-profit organization EUFOREA&#xD;
      (European Forum for Research and Education in Allergy and Airway diseases) has been conceived&#xD;
      to conduct real-life outcome research. The Galenus Health digital platform consisting of a&#xD;
      mobile application for patients and an online dashboard for physicians will be implemented in&#xD;
      each of the participating centres. The data will be centralized in a pseudonymized database&#xD;
      and will be the basis of the Chronic RhinoSinusitis Outcome Registry.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This real-life chronic rhinosinusitis outcome registry aims at longitudinal data collection&#xD;
      from patients attending specialist care centres across Europe.&#xD;
&#xD;
      As primary aim it intends to provide new insights on the burden of uncontrolled disease, the&#xD;
      impact on health-related quality of life, productivity loss as well as the effect of disease&#xD;
      severity and co-morbid disease on these outcome parameters.&#xD;
&#xD;
      In addition this outcome registry intends to identify patients eligible for type 2 targeted&#xD;
      biologic therapy, evaluate treatment effectiveness and markers of treatment response.&#xD;
&#xD;
      Beyond that direct and indirect costs for society related to chronic rhinosinusitis and its'&#xD;
      treatment will be studied.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Symptom severity total symptoms</measure>
    <time_frame>1 year</time_frame>
    <description>Baseline and change in VAS (visual analogue scale) total nasal, sinus, lung symptoms; 0 (Not at all bothersome) - 100 (Extremely bothersome) mm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptom severity - facial pain</measure>
    <time_frame>1 year</time_frame>
    <description>Baseline and change in VAS facial pain; 0 (Not at all bothersome) - 100 (Extremely bothersome) mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom severity - impaired smell</measure>
    <time_frame>1 year</time_frame>
    <description>Baseline and change in VAS impaired smell; 0 (Not at all bothersome) - 100 (Extremely bothersome) mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom severity - nasal blockage</measure>
    <time_frame>1 year</time_frame>
    <description>Baseline and change in VAS nasal blockage; 0 (Not at all bothersome) - 100 (Extremely bothersome) mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom severity - nasal secretions</measure>
    <time_frame>1 year</time_frame>
    <description>Baseline and change in VAS nasal secretions; 0 (Not at all bothersome) - 100 (Extremely bothersome) mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom severity - post-nasal drip</measure>
    <time_frame>1 year</time_frame>
    <description>Baseline and change in VAS post-nasal drip; 0 (Not at all bothersome) - 100 (Extremely bothersome) mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom severity - wheeze</measure>
    <time_frame>1 year</time_frame>
    <description>Baseline and change in VAS post-nasal drip; 0 (Not at all bothersome) - 100 (Extremely bothersome) mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom severity - dyspnoea</measure>
    <time_frame>1 year</time_frame>
    <description>Baseline and change in VAS dyspnoea; 0 (Not at all bothersome) - 100 (Extremely bothersome) mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom severity - chest tightness</measure>
    <time_frame>1 year</time_frame>
    <description>Baseline and change in VAS chest tightness; 0 (Not at all bothersome) - 100 (Extremely bothersome) mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom severity - cough</measure>
    <time_frame>1 year</time_frame>
    <description>Baseline and change in VAS cough; 0 (Not at all bothersome) - 100 (Extremely bothersome) mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom severity - itchy nose</measure>
    <time_frame>1 year</time_frame>
    <description>Baseline and change in VAS itchy nose; 0 (Not at all bothersome) - 100 (Extremely bothersome) mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom severity - itchy eyes</measure>
    <time_frame>1 year</time_frame>
    <description>Baseline and change in VAS itchy eyes; 0 (Not at all bothersome) - 100 (Extremely bothersome) mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom severity - sneeze</measure>
    <time_frame>1 year</time_frame>
    <description>Baseline and change in VAS sneeze; 0 (Not at all bothersome) - 100 (Extremely bothersome) mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease impact - work or school</measure>
    <time_frame>1 year</time_frame>
    <description>Baseline and change in VAS work or school; 0 (Not at all bothersome) - 100 (Extremely bothersome) mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease impact - sleep quality</measure>
    <time_frame>1 year</time_frame>
    <description>Baseline and change in VAS impact sleep quality; 0 (Not at all bothersome) - 100 (Extremely bothersome) mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease impact - daily life activities</measure>
    <time_frame>1 year</time_frame>
    <description>Baseline and change in VAS impact daily life activities; 0 (Not at all bothersome) - 100 (Extremely bothersome) mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare utilisation</measure>
    <time_frame>Registration at time of event</time_frame>
    <description>Number of care pathway events (healthcare provider visits, emergency room visits, hospitalisation, CT scan, endoscopic sinus surgery, bronchial thermoplastic, diagnostic tests)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication use</measure>
    <time_frame>Registration at time of new prescription and intakes</time_frame>
    <description>Changes in medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General health-related quality of life</measure>
    <time_frame>1 year</time_frame>
    <description>EQ-5D-5L (EuroQol-5Dimension-5Level) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRS-specific quality of life</measure>
    <time_frame>1 year</time_frame>
    <description>SNOT-22 (SinoNasal Outcome Test-22) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal Polyp Score</measure>
    <time_frame>1 year</time_frame>
    <description>Baseline and change in nasal polyp score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lund-Mackay score</measure>
    <time_frame>1 year</time_frame>
    <description>Baseline Lund-Mackay score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood eosinophil counts</measure>
    <time_frame>1 year</time_frame>
    <description>cells/mm^3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum total IgE</measure>
    <time_frame>1 year</time_frame>
    <description>IU/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Performance and Activity Impairment</measure>
    <time_frame>1 year</time_frame>
    <description>Work Performance and Activity Impairment questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalisations</measure>
    <time_frame>1 year</time_frame>
    <description>Number of hospitalisation for nose, sinus or lung problem in the past year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral corticosteroid use</measure>
    <time_frame>1 year</time_frame>
    <description>Courses of oral corticosteroid in the past year</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">4550</enrollment>
  <condition>Chronic Rhinosinusitis (Diagnosis)</condition>
  <arm_group>
    <arm_group_label>Chronic rhinosinusitis patients</arm_group_label>
    <description>Adult chronic rhinosinusitis patients capable of using a mobile application.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Users of the Galenus Health mobile application who reported a diagnosis with CRS will be&#xD;
        entered into the registry if they provided consent for scientific research. Confirmation of&#xD;
        CRS diagnosis by a physician will be performed via the web-based dashboard. The CRS&#xD;
        population includes both patients with and without nasal polyps, with and without asthma&#xD;
        co-morbidity, with or without former surgery, aged 18 years or above. Patients are included&#xD;
        into the registry with the aim of longitudinal follow up.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Physician diagnosis of Chronic RhinoSinusitis&#xD;
&#xD;
          -  Capable of using a mobile application on a smartphone&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with malignancies of the sinonasal cavity&#xD;
&#xD;
          -  Patients with inverted papilloma&#xD;
&#xD;
          -  Patients with unilateral disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sven F Seys, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Change Accelerator in Respiratory Care</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claus Bachert, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Ghent</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sven F Seys, PhD</last_name>
    <phone>0032 495 462585</phone>
    <email>sven.seys@galenus.health</email>
  </overall_contact>
  <location>
    <facility>
      <name>Graz University Hospital</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <contact>
      <last_name>Peter-Valentin Tomazic, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Peter-Valentin Tomazic, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clemens Holzmeister, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Ghent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Lara Derycke, PhD</last_name>
      <email>lara.derycke@ugent.be</email>
    </contact>
    <investigator>
      <last_name>Claus Bachert, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe Gevaert, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thibaut Van Zele, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Leen Cools, MSc</last_name>
      <email>leen.cools@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Peter W Hellings, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Jorissen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura Van Gerven, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Elisabeth Arndal, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christian von Buchwald, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vibeke Backer, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elisabeth Arndal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Anette Kjeldsen, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Anette Kjeldsen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bibi Lange, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kenneth Lenhardt-Larsen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dusseldorf University Clinic</name>
      <address>
        <city>DÃ¼sseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Martin Wagenmann, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Martin Wagenmann, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMC Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Sietze Reitsma, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Sietze Reitsma, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wytske Fokkens, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marjolein Cornet, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Akershus University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>1000</zip>
        <country>Norway</country>
      </address>
    </facility>
    <contact>
      <last_name>Andreas Steinsvik, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Andreas Steinsvik, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skane University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <contact>
      <last_name>Pernilla Sahlstrand-Johnson, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Pernilla Sahlstrand-Johnson, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal National Throat Nose Ear Hospital</name>
      <address>
        <city>London</city>
        <zip>WC1X 8DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Simon Gane, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Simon Gane, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guy's &amp; St. Thomas' Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 25, 2020</study_first_submitted>
  <study_first_submitted_qc>December 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>December 10, 2020</last_update_submitted>
  <last_update_submitted_qc>December 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

